Skip to main content
Log in

Antiviral prophylaxis cost effective for perinatal hep B prevention

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. hepatitis B surface antigen

Reference

  • Lee D, et al. Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea. Cost Effectiveness and Resource Allocation : 15 Feb 2018. Available from: URL: https://doi.org/10.1186/s12962-018-0088-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antiviral prophylaxis cost effective for perinatal hep B prevention. PharmacoEcon Outcomes News 797, 8 (2018). https://doi.org/10.1007/s40274-018-4717-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4717-5

Navigation